Histologic analysis of tumor-associated antigen WT1 specific CTL with related immunological environment in the brain of malignant brain tumor patients.

为揭示Wilms Tumor（WT1）肽疫苗对肿瘤患者的治疗机制，我们从多形性胶质母细胞瘤（GBM）患者的恶性脑肿瘤切片中原位鉴定WT1特异性细胞毒性T淋巴细胞（CTL）。此外，我们开发了WT1蛋白的半定量分析，并研究了WT1蛋白在多形性胶质母细胞瘤（GBM）的肿瘤细胞和肿瘤血管中的表达，与GBM相邻的正常组织（对照组织）相比。WT1在肿瘤血管中的表达明显强于对照组织。

For revealing the therapeutic mechanism of Wilms Tumor (WT1) peptide vaccination for cancer patients, we started research on in situ identification of WT1 specific cytotoxic T lymphocytes(CTLs) with malignant brain tumor sections from glioblastoma multiform (GBM) patients. Furthermore, we developed semi-quantitative analysis of WT1 protein and investigated expression of WT1 protein in tumor cells and tumor vessels of glioblastoma multiforme (GBM) compared to that of GBM adjacent normal-appearing tissues (control tissues). WT1 expression was significantly stronger in vessels of tumor lesions than that of control tissues.